SEC Form 3 filed by new insider Oakley Andrew John

$ONCO
Biotechnology: Pharmaceutical Preparations
Health Care
Get the next $ONCO alert in real time by email
SEC FORM 3 SEC Form 3
FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0104
Estimated average burden
hours per response: 0.5
1. Name and Address of Reporting Person*
Oakley Andrew John

(Last) (First) (Middle)
C/O ONCONETIX, INC.
201 E. FIFTH STREET, SUITE 1900

(Street)
CINCINNATI OH 45202

(City) (State) (Zip)
2. Date of Event Requiring Statement (Month/Day/Year)
02/24/2025
3. Issuer Name and Ticker or Trading Symbol
Onconetix, Inc. [ ONCO ]
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
5. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
Table II - Derivative Securities Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
No securities are beneficially owned.
/s/ Andrew Oakley 03/07/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
Get the next $ONCO alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$ONCO

DatePrice TargetRatingAnalyst
More analyst ratings

$ONCO
Press Releases

Fastest customizable press release news feed in the world

See more
  • Onconetix Signs Letter of Intent for Potential Business Combination with Ocuvex Therapeutics, Inc.

    CINCINNATI, April 08, 2025 (GLOBE NEWSWIRE) -- Onconetix, Inc. (NASDAQ:ONCO) ("Onconetix" or the "Company") (formerly Blue Water Biotech Inc.) and Ocuvex Therapeutics, Inc. ("Ocuvex"), a privately held biopharmaceutical company focused on the development and commercialization of ophthalmic therapeutic candidates to address highly prevalent diseases in need of new treatment options, today announced that they have signed a Non-Binding Letter of Intent contemplating a potential business combination transaction with Ocuvex. Andrew J. Oakley, Chairman of the Board of Onconetix, stated, "We are excited about the opportunity to combine forces with Ocuvex, whose pipeline of commercial and late c

    $ONCO
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Onconetix Announces Successful Clinical Validation of its Innovative Prostate Cancer Test Proclarix in a Danish cohort

    CINCINNATI, March 24, 2025 (GLOBE NEWSWIRE) -- Onconetix, Inc., (NASDAQ:ONCO) ("Onconetix" or the "Company"), (formerly Blue Water Biotech, Inc. (BWV)), a cancer diagnostics company focused on the research, development and commercialization of innovative solutions for oncology, today announced that new clinical data of Proclarix® was presented on March 23, 2025 during the 2025 European Association of Urology (EAU) congress, which data further demonstrates the strong clinical performance of Proclarix® in a Danish cohort. The primary approach for early detection of prostate cancer is through testing serum levels of prostate-specific antigen (PSA). However, given the limited cancer specific

    $ONCO
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Onconetix Announces New Clinical Data for its Innovative Prostate Cancer Test Proclarix Accepted for Presentation at 2025 European Association of Urology Congress

    CINCINNATI, March 19, 2025 (GLOBE NEWSWIRE) -- Onconetix, Inc., (NASDAQ:ONCO) ("Onconetix" or the "Company"), (formerly Blue Water Biotech, Inc. (BWV)), a cancer diagnostics company focused on the research, development and commercialization of innovative solutions for oncology, today announced that an abstract has been accepted for presentation at the 2025 European Association of Urology (EAU) congress taking place March 21-24, 2025, in Madrid, Spain. The presentation, titled, "Clinical Performance of Proclarix in Ruling Out Clinically Insignificant or No Prostate Cancer: Evaluation in a Danish Cohort," will highlight Proclarix performance results recently obtained from a study including

    $ONCO
    Biotechnology: Pharmaceutical Preparations
    Health Care

$ONCO
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$ONCO
SEC Filings

See more

$ONCO
Leadership Updates

Live Leadership Updates

See more
  • Virometix appoints Christina Ackermann as Chair and Tim Ramdeen as member of the Board

    Virometix AG, a privately held Swiss biotechnology company developing a new generation of fully synthetic vaccines to generate targeted and protective immune responses against infectious diseases and cancer today announces the appointment of Christina Ackermann as Chairwoman and Tim Ramdeen as a new member of its Board of Directors. Ms. Ackermann brings over 27 years of legal and management experience within the healthcare industries. Mr. Ramdeen has nearly a decade of experience in private equity, hedge fund investing, and capital markets. Christina Ackermann and Tim Ramdeen have led clinical and commercial companies through product development, growth, and commercialization while raising

    $ENTO
    $OCS
    $ONCO
    $VRNA
    Biotechnology: Pharmaceutical Preparations
    Health Care

$ONCO
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more